Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability

Reference

• Pharmaceutical Pricing and Reimbursement Information. Italy: Pharma profile. Available from: http://whocc.goeg.at/Literaturliste/Dokumente/CountryInformationReports/Italy_PPRI_2007.pdf 2007
   Google Scholar
• Lo Scalzo A, Donatini A, Orzella L, et al. Italy: health system review. Health Syst Transit 2009;11(6):1-216
   Google Scholar
• France G, Taroni F, Donatini A. The Italian health-care system. Health Econ 2005;14:S187-202
   PubMed Web of Science ®Google Scholar
• Bernardi A, Pegoraro R. Italian drug policy: ethical aims of essential assistance levels. Health Care Anal 2003;11(4):279-86
   PubMed Web of Science ®Google Scholar
• Habl C, Antony K, Arts D, et al. Surveying, assessing and analysing the pharmaceutical sector in the 25 EU Member States. Available from: http://ec.europa.eu/competition/mergers/studies_reports/oebig.pdf 2006.1-794
   Google Scholar
• Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. Econ Papers 461 | September 2012. European Commission; Brussels, Belgium: 2012. p. 1-64
   Google Scholar
• OECD. Health at a Glance 2013: OECD Indicators, OECD Publishing. Available from: http://dx.doi.org/10.1787/health_glance-2013-en
   Google Scholar
• OECD. Health at a Glance: Europe 2012, OECD Publishing. 2012. Available from: http://dx.doi.org/10.1787/9789264183896-en
   Google Scholar
• Assogenerici. Il farmaco generico: numeri e dimensioni [Aggionamento Giugno 2013]. 2013
   Google Scholar
• Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000;51:149-62
   PubMed Web of Science ®Google Scholar
• Garattini L, Ghislandi S. Off-patent drugs in Italy. A short-sighted view? Eur J Health Econ 2006;7:79-83
   PubMedGoogle Scholar
• Organisation for Economic Co-operation and Development. Roundtable on generic pharmaceuticals. 2010
   Google Scholar
• European Commission. Pharmaceutical sector inquiry: final report. 2009;1-533
   Google Scholar
• GaBi. Country focus: Italy. GaBi Online: Generic and Biosimilars Initiative (2012). Available from: www.gabionline.net/Country-Focus/Italy
   Google Scholar
• Dylst P, Vulto A, Simoens S. Overcoming challenges in market access of generic medicines in the European Union. J Generic Med 2012;9(1):21-8
   Google Scholar
• Anonymous. Italy hit by patent-linkage threat. Generics Bulletin 2011;2011:1
   Google Scholar
• GaBi. Italy asked to complly with marketing rules for generics. 2012. Available from: http://www.gabionline.net/layout/set/print/Generics/News/Italy-asked-to-comply-with-marketing-rules-for-generics
   Google Scholar
• European Commission. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. J EurUnion 2001; L0083/1-125
   Google Scholar
• Anonymous. Patent linkage could paralyse Italian firms. Generics Bulletin
   Google Scholar
• Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European contries - an overview. GaBi J 2012;1(2):93-100
   Google Scholar
• European Generic Medicines Association. 2011 market review. Available from: www.aeseg.es/restringido2/Market%20Review%202011%20%282%29.pdf
   Google Scholar
• AIFA. Automatic negotiation of generics and biosimilars. Updated 27 Feb 2014
   Google Scholar
• Vogler S. How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. Farmeconomia: Health Economics and Therapeutic Pathways 2012;13(3):29-41
   Google Scholar
• Reinaud F. Generic drug price trends - a comparison across France, Germany, Italy, Spain and the UK. Available from: http://healthcare.blogs.ihs.com/2012/01/06/generic-drug-price-trends-france-germany-italy-spain-uk/(2012)
   Google Scholar
• IMS Health. Analyse des prix des génériques en Europe. 2014
   Google Scholar
• Ghislandi S, Armeni P, Jommi C. The impact of generic reference pricing in Italy, a decade on. Eur J Health Econ 2013;14:959-69
   PubMed Web of Science ®Google Scholar
• Garattini L, Cornago D. Pharmacuetical policy in Italy: theory, politics and practice. Eur J Health Econ 2006;7:89-90
   PubMedGoogle Scholar
• Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Review 2011;4(2):22-32
   Google Scholar
• Vogler S, Zimmermann N, Habl C, et al. Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review 2012;5(1):38-46
   PubMedGoogle Scholar
• Ghislandi S, Krulichova I, Garattini L. Pharmaceutical policy in Italy: towards a structural change? Health Policy 2005;72:53-63
   PubMed Web of Science ®Google Scholar
• Simoens S, De Coster S. Sustaining generic medicines markets in Europe. Availablae from www.assogenerici.org/articolihome/simoens-report_2006-04.pdf 2006.1-100
   Google Scholar
• Dylst P, Vulto A, Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev of Pharmacoecon Outcomes Res 2011;11(6):729-37
   PubMed Web of Science ®Google Scholar
• GaBi. Italian physicians’ negative attitude to generics. 2012. Available from: http://www.gabionline.net/Generics/General/Italian-physicians-negative-attitude-to-generics
   Google Scholar
• Pisani J, Bonduelle Y. Opportunities and barriers in the biosimilar market: Evolution or revolution for generic companies? 2006. Available from: www.ableindia.in/wp-content/uploads/2014/03/report-opportunities-and-barriers-in-the-biosimilar-market.pdf
   Google Scholar
• LEGGE 30 luglio 2010, n. 122. Conversione in legge, con modificazioni, del decreto-legge 31 maggio. 2010, n. 78, recante misure urgenti in materia di stabilizzazione finanziaria e di competitivita’ economica. (10G0146). 2014. Available from: http://www.altalex.com/index.php?idnot=11695
   Google Scholar
• Decreto-legge 28 aprile 2009, n. 39, "Interventi urgenti in favore delle popolazioni colpite dagli eventi sismici nella regione Abruzzo nel mese di aprile 2009 e ulteriori interventi urgenti di protezione civile. (09G0047)", pubblicato nella Gazzetta Ufficiale n. 97 del 28 aprile 2009 (Rettifica G.U. n. 102 del 5 maggio 2009). 2014. Available from: http://www.altalex.com/index.php?idnot=11219
   Google Scholar
• CBI. CBI market survey. The pharmaceutical products market in the EU. Available from: http://www.cbi.eu/system/files/marketintel/2010_-_pharmaceutical_products_-_EU.pdf 2010.1-46
   Google Scholar
• Dylst P, Simoens S. Does the market share of generic medicines influence the price level? A European analysis. Pharmacoeconomics 2011;29(10):875-82
   PubMed Web of Science ®Google Scholar
• Dylst P, Vulto A, Simoens S. How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing? Pharmacy Practice 2012;10(1):3-8
   PubMedGoogle Scholar
• Colombo G, Agabiti-Rosei E, Margonato A, et al. Off-patent generic medicines vs. off-patent brand medicines for six reference drugs: A retrospective claims data study from five local healthcare units in the Lombardy Region of Italy. PLoS One 2013;8(12):e82990
   Web of Science ®Google Scholar
• Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res 2013;13(1):59-72
   PubMed Web of Science ®Google Scholar
• GaBi. Country focus: France. GaBi online - Generics and Biosimilars Initiative. 2012. Available from: www.gabionline.net/Country-Focus/France
   Google Scholar
• Anonymous. French sales lifted by incentive scheme. Generics Bulletin
   Google Scholar